2046 related articles for article (PubMed ID: 30922314)
1. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3.
Niu Y; Lin Z; Wan A; Chen H; Liang H; Sun L; Wang Y; Li X; Xiong XF; Wei B; Wu X; Wan G
Mol Cancer; 2019 Mar; 18(1):46. PubMed ID: 30922314
[TBL] [Abstract][Full Text] [Related]
2. FTO demethylates m6A modifications in HOXB13 mRNA and promotes endometrial cancer metastasis by activating the WNT signalling pathway.
Zhang L; Wan Y; Zhang Z; Jiang Y; Lang J; Cheng W; Zhu L
RNA Biol; 2021 Sep; 18(9):1265-1278. PubMed ID: 33103587
[TBL] [Abstract][Full Text] [Related]
3. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer.
Chen X; Xu M; Xu X; Zeng K; Liu X; Pan B; Li C; Sun L; Qin J; Xu T; He B; Pan Y; Sun H; Wang S
Mol Cancer; 2020 Jun; 19(1):106. PubMed ID: 32552762
[TBL] [Abstract][Full Text] [Related]
4.
Chen F; Chen Z; Guan T; Zhou Y; Ge L; Zhang H; Wu Y; Jiang GM; He W; Li J; Wang H
Cancer Res; 2021 Jun; 81(11):2847-2860. PubMed ID: 33795252
[TBL] [Abstract][Full Text] [Related]
5. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner.
Guo X; Li K; Jiang W; Hu Y; Xiao W; Huang Y; Feng Y; Pan Q; Wan R
Mol Cancer; 2020 May; 19(1):91. PubMed ID: 32429928
[TBL] [Abstract][Full Text] [Related]
6. RNA m6A demethylase FTO-mediated epigenetic up-regulation of LINC00022 promotes tumorigenesis in esophageal squamous cell carcinoma.
Cui Y; Zhang C; Ma S; Li Z; Wang W; Li Y; Ma Y; Fang J; Wang Y; Cao W; Guan F
J Exp Clin Cancer Res; 2021 Sep; 40(1):294. PubMed ID: 34544449
[TBL] [Abstract][Full Text] [Related]
7. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
8. Novel positioning from obesity to cancer: FTO, an m
Chen J; Du B
J Cancer Res Clin Oncol; 2019 Jan; 145(1):19-29. PubMed ID: 30465076
[TBL] [Abstract][Full Text] [Related]
9. Dysregulation of USP18/FTO/PYCR1 signaling network promotes bladder cancer development and progression.
Song W; Yang K; Luo J; Gao Z; Gao Y
Aging (Albany NY); 2021 Jan; 13(3):3909-3925. PubMed ID: 33461172
[TBL] [Abstract][Full Text] [Related]
10. Increased N6-methyladenosine causes infertility is associated with FTO expression.
Ding C; Zou Q; Ding J; Ling M; Wang W; Li H; Huang B
J Cell Physiol; 2018 Sep; 233(9):7055-7066. PubMed ID: 29384212
[TBL] [Abstract][Full Text] [Related]
11. FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner.
Huang J; Sun W; Wang Z; Lv C; Zhang T; Zhang D; Dong W; Shao L; He L; Ji X; Zhang P; Zhang H
J Exp Clin Cancer Res; 2022 Jan; 41(1):42. PubMed ID: 35090515
[TBL] [Abstract][Full Text] [Related]
12. FTO-Dependent N
Mathiyalagan P; Adamiak M; Mayourian J; Sassi Y; Liang Y; Agarwal N; Jha D; Zhang S; Kohlbrenner E; Chepurko E; Chen J; Trivieri MG; Singh R; Bouchareb R; Fish K; Ishikawa K; Lebeche D; Hajjar RJ; Sahoo S
Circulation; 2019 Jan; 139(4):518-532. PubMed ID: 29997116
[TBL] [Abstract][Full Text] [Related]
13. RNA N6-methyladenosine demethylase FTO promotes osteoporosis through demethylating Runx2 mRNA and inhibiting osteogenic differentiation.
Wang J; Fu Q; Yang J; Liu JL; Hou SM; Huang X; Cao JS; Liu TL; Wang KZ
Aging (Albany NY); 2021 Sep; 13(17):21134-21141. PubMed ID: 34496349
[TBL] [Abstract][Full Text] [Related]
14. Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression.
Du C; Lv C; Feng Y; Yu S
J Exp Clin Cancer Res; 2020 Oct; 39(1):223. PubMed ID: 33087165
[TBL] [Abstract][Full Text] [Related]
15. LncRNA FTO-IT1 promotes glycolysis and progression of hepatocellular carcinoma through modulating FTO-mediated N6-methyladenosine modification on GLUT1 and PKM2.
Wang F; Hu Y; Wang H; Hu P; Xiong H; Zeng Z; Han S; Wang D; Wang J; Zhao Y; Huang Y; Zhuo W; Lv G; Zhao G
J Exp Clin Cancer Res; 2023 Oct; 42(1):267. PubMed ID: 37840133
[TBL] [Abstract][Full Text] [Related]
16. N6-methyladenosine demethylase FTO enhances chemo-resistance in colorectal cancer through SIVA1-mediated apoptosis.
Lin Z; Wan AH; Sun L; Liang H; Niu Y; Deng Y; Yan S; Wang QP; Bu X; Zhang X; Hu K; Wan G; He W
Mol Ther; 2023 Feb; 31(2):517-534. PubMed ID: 36307991
[TBL] [Abstract][Full Text] [Related]
17. Level of N6-Methyladenosine in Peripheral Blood RNA: A Novel Predictive Biomarker for Gastric Cancer.
Ge L; Zhang N; Chen Z; Song J; Wu Y; Li Z; Chen F; Wu J; Li D; Li J; Wang C; Wang H; Wang J
Clin Chem; 2020 Feb; 66(2):342-351. PubMed ID: 32040577
[TBL] [Abstract][Full Text] [Related]
18. N6-methyladenosine methylation regulator FTO promotes oxidative stress and induces cell apoptosis in ovarian cancer.
Wu J; Wang X; Li X
Epigenomics; 2022 Dec; 14(23):1509-1522. PubMed ID: 36815224
[TBL] [Abstract][Full Text] [Related]
19. The tumor-suppressive effects of alpha-ketoglutarate-dependent dioxygenase FTO via N6-methyladenosine RNA methylation on bladder cancer patients.
Yi W; Yu Y; Li Y; Yang J; Gao S; Xu L
Bioengineered; 2021 Dec; 12(1):5323-5333. PubMed ID: 34499008
[TBL] [Abstract][Full Text] [Related]
20. FTO facilitates cancer metastasis by modifying the m
Gao L; Wang A; Chen Y; Cai X; Li Y; Zhao J; Zhang Y; Zhang W; Zhu J; Zeng Y; Liu Z; Huang JA
Cell Commun Signal; 2023 Nov; 21(1):311. PubMed ID: 37919739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
